September 1, 2017 08:55 AM EDT

NEA-backed Nightstar Therapeutics sets sights on an $86M IPO to fund PhIII gene therapy study

John Carroll

Editor & Founder

Two months after banking a $45 million crossover round from some top biotech investors, Oxford gene therapy spinout Nightstar Therapeutics has penciled in an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

NEA-backed Nightstar Therapeutics sets sights on an $86M IPO to fund PhIII gene therapy study

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Regeneron plans to buy 23andMe for $256M

David Liu, Sam Sternberg unveil new way to insert big genes in human cells

Prime Medicine sidelines only clinical program, replaces CEO and lays off some staff

Exclusive: CellCentric collects $120M to treat multiple myeloma with a capsule

Intellia's CRISPR therapy likely causes 'permanent' gene knockdown in ATTR amyloidosis

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

NEA-backed Night­star Ther­a­peu­tics sets sights on an $86M IPO to fund PhI­II gene ther­a­py study

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

NEA-backed Nightstar Therapeutics sets sights on an $86M IPO to fund PhIII gene therapy study